---
document_datetime: 2025-07-25 10:52:24
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mysimba-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: mysimba-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 11.7362031
conversion_datetime: 2025-12-19 00:20:58.797716
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Mysimba

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|----------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10366 /202409  | Periodic Safety Update EU Single assessment - naltrexone / bupropion | 25/04/2025                          | 17/07/2025                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10366/202409. |
| A20/0065             |                                                                      | 27/03/2025                          | 22/05/2025                                  | SmPC, Annex II and PL            |                                                                                                                                            |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IAIN/0074   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 15/01/2025   | 22/05/2025   | SmPC, Labelling and PL   |                           |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------|
| IB/0072/G   | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its | 13/01/2025   | n/a          |                          | corresponding test method |
| II/0066     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/11/2024   | n/a          |                          |                           |
| II/0063     | To update sections 4.3, 4.4, 4.5 and 4.8 of the SmPC and related PIL sections following PRAC Assessment Report recommendations received during PSUSA/00010366/202209 procedure, on 21 April 2023: The MAH is requested to submit a Type II variation, within 30 days following the conclusion of the to enhance the existing risk                                                                                                                                                                                                                                              | 14/11/2024   | 22/05/2025   | SmPC and PL              | PSUSA, in order           |

<div style=\"page-break-after: always\"></div>

|           | minimisation measures. This should include a comprehensive proposal to update and streamline the relevant wording on opioids in sections 4.3, 4.4, 4.5 and 4.8 of the SmPC (PL accordingly). In addition, the MAH should specify the opioid-free interval prior to starting NB treatment more precisely (e.g., whether for certain substances the period is longer than currently recommended). Furthermore, the MAH should clarify the current recommendation in the PL that a blood test (referring to opioids) may be carried out prior to starting NB and whether the SmPC should be updated accordingly. In the light of the above proposals to be made, the MAH should discuss possible further measures to address this risk. The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with   |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0071   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/10/2024 | n/a |
| IB/0070/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 26/06/2024 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | in the manufacturing process B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products   |            |            |    |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUSA/10366 /202309 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/04/2024 | n/a        |    | PRAC Recommendation - maintenance |
| IAIN/0069/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                        | 14/02/2024 | n/a        |    |                                   |
| N/0068              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/01/2024 | 22/05/2025 | PL |                                   |
| IA/0064/G           | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 04/07/2023 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

|                     | deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   |            |            |                 |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10366 /202209 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                                         | 26/04/2023 | 04/07/2023 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10366/202209. |
| IB/0062             | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                               | 27/02/2023 | 04/07/2023 | SmPC and PL     |                                                                                                                                            |
| II/0054             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                | 09/02/2023 | n/a        |                 |                                                                                                                                            |
| IAIN/0059           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                   | 15/12/2022 | 04/07/2023 | Annex II and PL |                                                                                                                                            |
| PSUSA/10366 /202109 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                                         | 22/04/2022 | 21/06/2022 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10366/202109. |
| N/0057              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                             | 16/05/2022 | 04/07/2023 | PL              |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| II/0050             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                              | 13/01/2022   | n/a        |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0055/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 21/12/2021   | n/a        |             |                                                                                                                                            |
| IA/0052             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                        | 10/12/2021   | n/a        |             |                                                                                                                                            |
| N/0051              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                           | 15/11/2021   | 21/06/2022 | PL          |                                                                                                                                            |
| PSUSA/10366 /202009 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                       | 22/04/2021   | 17/06/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10366/202009. |
| IA/0049/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of                                                                                                   | 26/02/2021   | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| II/0042     | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                                                                                                                                                                                                  | 14/01/2021   | n/a        |             |                     |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------|
| IAIN/0048/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from manufacturer | 06/01/2021   | n/a        |             | an already approved |
| IA/0047/G   | This was an application for a group of variations. B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                  | 09/12/2020   | n/a        |             | procedure           |
| N/0045      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                    | 26/11/2020   | 17/06/2021 | PL          |                     |
| II/0044/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                  | 01/10/2020   | 17/06/2021 | SmPC and PL |                     |

<div style=\"page-break-after: always\"></div>

|           | of product information resulting from PRAC Assessment Report request in PSUSA/00010366/201909: - Introduction of a warning concerning the interaction between Naltrexone/Bupropion and Digoxin in SmPC section 4.5 and related PL section. - Update of SmPC section 4.8 and related PL section on drug-induced lupus erythematosus with Naltrexone/Bupropion and its individual substance. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with   |            |            |    | Update   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|----------|
| N/0043    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 08/09/2020 | 17/06/2021 | PL |          |
| IB/0040/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/08/2020 | n/a        |    |          |

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate/reagent - Other variation                                                                                                                                                                                             |            |            |                                  |                                                                                                                                                                                                                                                                                                                                              |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10366 /201909 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                        | 30/04/2020 | 03/07/2020 |                                  | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10366/201909.                                                                                                                                                                                                   |
| IB/0041             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                      | 19/06/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                              |
| N/0039              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                            | 04/03/2020 | 03/07/2020 | PL                               |                                                                                                                                                                                                                                                                                                                                              |
| N/0037              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                            | 03/03/2020 | 03/07/2020 | PL                               |                                                                                                                                                                                                                                                                                                                                              |
| IAIN/0038           | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                         | 17/01/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                              |
| R/0033              | Renewal of the marketing authorisation.                                                                                                                                                                                                     | 14/11/2019 | 16/01/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Mysimba in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                        |
| II/0029/G           | This was an application for a group of variations. Group of variations consisting of: C.I.3.b: to update section 4.8 on the list of adverse drug reactions and their corresponding frequencies following the PRAC outcome on PSUR procedure | 19/09/2019 | 24/10/2019 | SmPC and PL                      | A single-dose pharmacokinetic study in patients with varying degrees of hepatic impairment showed that in patients with mild hepatic impairment, there was a modest increase in naltrexone concentrations. In patients with moderate and severe hepatic impairment, increases in the maximum concentration of naltrexone of ~6- and ~30-fold |

<div style=\"page-break-after: always\"></div>

| (PSUSA/10366/201709). C.I.4: to update sections 4.2, 4.4 and 5.2 of the SmPC to reflect the results from a phase I open label parallel study to evaluate the pharmacokinetics of a single oral dose of extended-release combination of naltrexone and bupropion in subjects with normal hepatic function or varying degrees of impaired hepatic function. Consequently, the recommendation to not use naltrexone/bupropion in patients with mild hepatic impairment has been replaced with dosing recommendations in these patients. Similar recommendations have also been included for patients with moderate and severe renal impairment. Section 4.4 has also been simplified by removing the warnings for contraindications as these are adequately reflected in section 4.3 of the SmPC. An updated RMP (version 12.4) was also submitted. In addition, the MAH took the opportunity to update the warning on lactose to be in accordance with EC guideline on Guideline on \"Excipients in the labelling and package leaflet of medicinal products for human use\". C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH C.I.4 - Change(s) in the SPC, Labelling or PL due to   | were observed for the moderate and severe patients respectively. Naltrexone / bupropion is contraindicated patients with severe hepatic impairment and is not recommended in patients with moderate hepatic impairment. In patients with mild hepatic impairment, maximum recommended daily dose for naltrexone / bupropion should be reduced to two tablets (one tablet the morning and one tablet in the evening). It is recommended that patients with mild hepatic impairment initiate treatment with one tablet in the morning for first week of treatment, and escalate to one tablet in morning and one tablet in the evening from Week 2 onwards.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IB/0034/G           | This was an application for a group of variations. B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)   | 19/10/2019   | n/a        |                 |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| N/0035              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 01/08/2019   | 24/10/2019 | PL              |                                                                                                                                            |
| PSUSA/10366 /201809 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26/04/2019   | 28/06/2019 |                 | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10366/201809. |
| IAIN/0032/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                            | 29/03/2019   | 28/06/2019 | Annex II and PL |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                              |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0030/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 26/10/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                              |
| N/0028              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                              | 02/07/2018 | 28/06/2019 | PL          |                                                                                                                                                                                                                                                                                                                              |
| PSUSA/10366 /201709 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                                                                                                                                                                                          | 26/04/2018 | 02/07/2018 | SmPC        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10366/201709.                                                                                                                                                                                   |
| N/0027              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                              | 05/03/2018 | 02/07/2018 | PL          |                                                                                                                                                                                                                                                                                                                              |
| II/0023             | Update of sections 4.2, 4.3, 4.4, 4.8 and 5.2 of the SmPC in order to update the dosage recommendation and safety information for patients with moderate renal impairment based on final results from study NaltrexBuprop-1006 - A Phase 1, Open-Label, Parallel Study to Evaluate the                                                                                                                                                                                                        | 14/12/2017 | 26/01/2018 | SmPC and PL | The SmPC sections 4.2, 4.3, 4.4, 4.8 and 5.2 has been updated in order to update the dosage recommendation and safety information for patients with moderate renal impairment based on final results from study NaltrexBuprop-1006 - A Phase 1, Open-Label, Parallel Study to Evaluate the Pharmacokinetics of a Single Oral |

<div style=\"page-break-after: always\"></div>

|                     | Pharmacokinetics of a Single Oral Dose of Extended- Release Combination of Naltrexone and Bupropion in Subjects With Normal Renal Function or Varying Degrees of Impaired Renal Function. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                 |            |            |      | Dose of Extended-Release Combination of Naltrexone and Bupropion in Subjects With Normal Renal Function or Varying Degrees of Impaired Renal Function. The proposed update removes the contraindication for patients with severe renal impairment, provides new information on the posology and additional warning that the maximum recommended daily dose for naltrexone / bupropion should be reduced for this patient population. The PL have been updated accordingly.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10366 /201703 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                                                                    | 12/10/2017 | 08/12/2017 | SmPC | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10366/201703.                                                                                                                                                                                                                                                                                                                                   |
| IB/0026             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                               | 05/12/2017 | 26/01/2018 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0024             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                          | 09/11/2017 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0022/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 11/10/2017 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           | - Change in test procedure for AS or material/reagent/intermediate - Minor to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                        | B.I.b.2.a starting changes   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------|
| IB/0021   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 21/09/2017 | 08/12/2017 | SmPC, Labelling and PL | the range of the             |
| II/0017   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 14/09/2017 | n/a        |                        |                              |
| N/0020    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/09/2017 | 08/12/2017 | PL                     |                              |
| IB/0018/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the | 04/07/2017 | n/a        |                        |                              |

<div style=\"page-break-after: always\"></div>

|                     | relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10366 /201609 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 21/04/2017 | 23/06/2017 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10366/201609.                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0015             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/06/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0014             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/06/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0010             | Update of sections 4.4 and 4.8 of the SmPC to update existing warnings on seizures and blood pressure increase and to include abdominal discomfort, anxiety, dyspepsia, fatigue, hallucination, headache, hypertension, insomnia, irritability, and rash as adverse drug reactions for the Naltrexone/ Bupropion combination with a frequency unknown based on the results of study NB-CVOT (a Multicenter, Randomized, Double-Blind, Placebo- Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects with Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR). In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. | 22/06/2017 | 08/12/2017 | SmPC and PL | In a cardiovascular outcomes trial (CVOT) of patients at increased risk of a cardiovascular event, mean increases from baseline in systolic and diastolic blood pressure of approximately 1 mmHg compared to placebo were observed. This incidence of seizure, along with incidence of seizure in subjects who received naltrexone / bupropion at the time of interim analysis in a large, ongoing cardiovascular outcomes trial (CVOT), was no higher than the seizure rate with bupropion as a single agent at approved doses. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | in this Annex which involve the submission studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |    | elsewhere of   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|----------------|
| II/0013/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.g.2 - Introduction of a post approval change protocol related to the finished product | 01/06/2017 | n/a        |    | management     |
| N/0016    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/03/2017 | 23/06/2017 | PL |                |

<div style=\"page-break-after: always\"></div>

| II/0011             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                         | 23/02/2017   | n/a        |      |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-----------------------------------|
| IAIN/0008/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                         | 09/11/2016   | 12/12/2016 | SmPC |                                   |
| PSUSA/10366 /201603 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 27/10/2016   | n/a        |      | PRAC Recommendation - maintenance |
| II/0005/G           | This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated | 15/09/2016   | n/a        |      |                                   |

<div style=\"page-break-after: always\"></div>

|                     | by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                 |            |            |    |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| N/0007              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                           | 22/08/2016 | 12/12/2016 | PL |                                   |
| II/0003/G           | This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 26/05/2016 | n/a        |    |                                   |
| N/0004              | Inclusion of the list of local representatives at the end of the package leaflet. In addition, the MAH took the opportunity to make linguistic amendments in the Bulgarian, Croatian, Czech, Hungarian, Lithuanian, Polish, Romanian, and Slovenian labelling and package leaflets. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                       | 20/05/2016 | 12/12/2016 | PL |                                   |
| PSUSA/10366 /201509 | Periodic Safety Update EU Single assessment - naltrexone / bupropion                                                                                                                                                                                                                                                                                                                                                                                       | 14/04/2016 | n/a        |    | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0001   | A.1 - Administrative change - Change in the name and/or address of the MAH   | 03/12/2015   | 12/12/2016   | SmPC, Labelling and PL   |
|-------------|------------------------------------------------------------------------------|--------------|--------------|--------------------------|